MarketPulse

imetelstat

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron Sets May 6 Earnings Call as RYTELO Expansion Accelerates

Geron Corporation will report Q1 2026 results on May 6, advancing its approved telomerase inhibitor RYTELO and Phase 3 myelofibrosis trial.
GERNfinancial resultsclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron to Share Pipeline Progress at Needham Conference as RYTELO® Gains Market Traction

Geron Corporation will discuss its commercial-stage telomerase inhibitor platform at the Needham Healthcare Conference on April 13, highlighting RYTELO® adoption and ongoing Phase 3 trials in myelofibrosis.
GERNclinical trialbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Geron Posts $184M in Annual RYTELO Revenue, Guides 2026 Sales Growth

Geron's RYTELO generated $184M in 2025 revenue. The company guides 2026 sales of $220-240M, driven by domestic expansion and international opportunities.
GERNfinancial resultsFDA approval